SAFETY OF TO FACITINIB COMPARED TO BIOLOGICAL DMARDS IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO METHOTREXATE: OVERVIEW OF SYSTEMATIC REVIEWS

被引：0
|
作者：
Reyes, J. M. [1 ]
Rodriguez, A. [2 ]
机构：
[1] Pfizer SAS, Bogota, Colombia
[2] Univ Nacl Colombia, Bogota, Colombia
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.887
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS2
引用
收藏
页码：A152 / A153
页数：4
相关论文
共 50 条
  • [41] EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS
    Combe, Bernard
    Kivitz, Alan
    Tanaka, Yoshiya
    van der Heijde, Desiree
    Matzkies, Franziska
    Bartok, Beatrix
    Ye, Lei
    Guo, Ying
    Tasset, Chantal
    Sundy, John
    Mozaffarian, Neelufar
    Landewe, Robert B. M.
    Bae, Sang-Cheol
    Keystone, Edward C.
    Nash, Peter
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 77 - 78
  • [42] EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS
    Combe, B.
    Kivitz, A.
    Tanaka, Y.
    Van der Heijde, D.
    Simon-Campos, J. A.
    Baraf, H. S. B.
    Kumar, U.
    Matzkies, F.
    Bartok, B.
    Ye, L.
    Guo, Y.
    Tasset, C.
    Sundy, J.
    Jahreis, A.
    Mozaffarian, N.
    Landewe, R. B. M.
    Bae, S. C.
    Keystone, E.
    Nash, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 316 - 317
  • [43] EFFICACY OF ADDING IGURATIMOD THERAPY IN RHEUMATOID ARTHRITIS PATIENTS WHO HAD INADEQUATE RESPONSE TO BIOLOGIC DMARDS
    Miyamoto, T.
    Yamazaki, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1470 - 1470
  • [44] Safety and Efficacy of Abatacept Over 4 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in the AIM Trial
    Russell, A. S.
    Kremer, J. M.
    Emery, P.
    Abud-Mendoza, C.
    Szechinski, J.
    Zhao, C.
    Becker, J-C
    Westhovens, R.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2608 - 2609
  • [45] Safety and efficacy of abatacept over 4 years of treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate in the AIM trial
    Kremer, J. M.
    Russell, A. S.
    Emery, P.
    Abud-Mendoza, C.
    Szechinski, J.
    Zhao, C.
    Becker, J-C
    Westhovens, R.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S308 - S309
  • [46] Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results
    Combe, Bernard
    Kivitz, Alan
    Tanaka, Yoshiya
    van der Heijde, Desiree
    Matzkies, Franziska
    Bartok, Beatrix
    Ye, Lei
    Guo, Ying
    Tasset, Chantal
    Sundy, John
    Mozaffarian, Neelufar
    Landewe, Robert B. M.
    Bae, Sang-Cheol
    Keystone, Edward
    Nash, Peter
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [47] EFFICACY AND SAFETY OF ADALIMUMAB WITH LOW AND HIGH DOSE-METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: THE RANDOMISED CONTROLLED MIRACLE STUDY
    Tamai, H.
    Ikeda, K.
    Miyamoto, T.
    Taguchi, H.
    Kuo, C. F.
    Shin, K.
    Hirata, S.
    Okano, Y.
    Sato, S.
    Yasuoka, H.
    Choi, I. A.
    Park, S. H.
    Weng, M. Y.
    Kuwana, M.
    Lee, Y. J.
    Ishii, T.
    Kim, J.
    Kameda, H.
    Kojima, T.
    Baek, H. J.
    Hsu, P. N.
    Huang, C. M.
    Cheng, T. T.
    Sung, W. Y.
    Taninaga, T.
    Mori, M.
    Miyagishi, H.
    Sato, Y.
    Takeuchi, T.
    Kaneko, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 42 - 43
  • [48] Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs - a systematic review and network meta-analysis
    Jansen, Jeroen P.
    Buckley, Felicity
    Dejonckheere, Fred
    Ogale, Sarika
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2014, 12
  • [49] Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis
    Jeroen P Jansen
    Felicity Buckley
    Fred Dejonckheere
    Sarika Ogale
    Health and Quality of Life Outcomes, 12
  • [50] Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs
    Narvaez, J.
    Diaz-Torne, C.
    Ruiz, J. M.
    Hernandez, M. V.
    Torrente-Segarra, V.
    Ros, S.
    Rodriguez de la Serna, A.
    Diaz-Lopez, C.
    Sanmarti, R.
    Nolla, J. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (06) : 991 - 997
12345